Shares of Seattle Genetics rose $1.55, or 3.3%, in after-hours trading on Aug. 17 after the firm won a third US indication for its CD30-directed antibody-drug conjugate Adcetris (brentuximab vedotin) from an accelerated to a regular approval – classical Hodgkin lymphoma (HL) in patients at high risk of relapse or progression as post-autologous hematopoietic stem-cell transplantation (auto-HSCT) consolidation.
Shares of Seattle Genetics rose $1.55, or 3.3%, in after-hours trading on Aug. 17 after the firm won a third US indication for its CD30-directed antibody-drug conjugate Adcetris (brentuximab vedotin) from an accelerated to a regular approval – classical Hodgkin lymphoma (HL) in patients at high risk of relapse or progression as post-autologous hematopoietic stem-cell transplantation (auto-HSCT) consolidation.
The approval was based on data from Seattle Genetics' Phase III AETHERA study.
CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”
Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.
The company announced data from patients enrolled after a protocol amendment designed to bring the study in line with non-muscle invasive bladder cancer (NMIBC) standards of care.
A long time on the ropes, the US firm is now well-financed to advance potential candidates for essential thrombocythemia and myelofibrosis into the clinic.
A long time on the ropes, the US firm is now well-financed to advance potential candidates for essential thrombocythemia and myelofibrosis into the clinic.
The biopharma plans to advance the PD-1 agonist in rheumatoid arthritis despite its failure in ulcerative colitis.
Small study fails to turn up efficacy signals in the major depressive disorder candidate, leaving Neurocrine with one remaining depression candidate in development.
